Associations - dacarbazine

No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	gemcitabine + dacarbazine Sensitive: A2 - Guideline gemcitabine + dacarbazine Sensitive : A2	gemcitabine + dacarbazine Sensitive: A2 - Guideline gemcitabine + dacarbazine Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	gemcitabine + dacarbazine Sensitive: A2 - Guideline gemcitabine + dacarbazine Sensitive : A2	gemcitabine + dacarbazine Sensitive: A2 - Guideline gemcitabine + dacarbazine Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive : A2	paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3
ATRX mutation	Leiomyosarcoma	ATRX mutation	Leiomyosarcoma	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3
TP53 mutation	Leiomyosarcoma	TP53 mutation	Leiomyosarcoma	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3
BRAF mutation	Mucosal Melanoma	BRAF mutation	Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3
NRAS mutation	Mucosal Melanoma	NRAS mutation	Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3
KIT mutation	Mucosal Melanoma	KIT mutation	Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3
CD8 elevation + BRAF V600	Melanoma	CD8 elevation + BRAF V600	Melanoma	dacarbazine Sensitive: C3 – Early Trials dacarbazine Sensitive : C3	dacarbazine Sensitive: C3 – Early Trials dacarbazine Sensitive : C3
SKAP2-BRAF fusion	Melanoma	SKAP2-BRAF fusion	Melanoma	pembrolizumab + nivolumab + trametinib + ipilimumab + dacarbazine Resistant: C4 – Case Studies pembrolizumab + nivolumab + trametinib + ipilimumab + dacarbazine Resistant : C4	pembrolizumab + nivolumab + trametinib + ipilimumab + dacarbazine Resistant: C4 – Case Studies pembrolizumab + nivolumab + trametinib + ipilimumab + dacarbazine Resistant : C4
BRAF wild-type	Melanoma	BRAF wild-type	Melanoma	dacarbazine Sensitive: C4 – Case Studies dacarbazine Sensitive : C4	dacarbazine Sensitive: C4 – Case Studies dacarbazine Sensitive : C4
CD133 expression	Glioblastoma	CD133 expression	Glioblastoma	dacarbazine Sensitive: D – Preclinical dacarbazine Sensitive : D	dacarbazine Sensitive: D – Preclinical dacarbazine Sensitive : D
ROR2 overexpression	Melanoma	ROR2 overexpression	Melanoma	dacarbazine Resistant: D – Preclinical dacarbazine Resistant : D	dacarbazine Resistant: D – Preclinical dacarbazine Resistant : D

dacarbazine

Associations
(22)

Associations
(22)

dacarbazine

Associations(22)

Associations(22)

Associations
(22)

Associations
(22)